Literature DB >> 3731971

Evaluation of postprandial serum bile acid response as a test of hepatic function.

S M Greenfield, R D Soloway, R L Carithers, K Soper, S G Silva de Barros, W F Balistreri.   

Abstract

Commercial assays for serum bile acids (SBA) have made this measurement practical. The purpose of this study was to examine the utility of SBA measured every 30 min after a standardized meal in controls and in patients with acute viral hepatitis, cholestasis, and anicteric cirrhosis. In five controls, repeated examination of the area under the bile acid curve (AUC) was not statistically different, whereas the fasting and 2-hr postprandial levels were significantly different. In the group of patients with anicteric cirrhosis, AUC identified disease in 18/20 using total serum bile acids (TSBAs) and in 15/20 using cholylglycine (CG). AUC can be calculated from three samples obtained at 0, 60, and 120 min without losing the sensitivity achieved with seven serial samples. SGOT, alkaline phosphatase, and serum albumin were compared for sensitivity to the total SBA response curve in 20 patients with anicteric cirrhosis. SGOT and alkaline phosphatase identified only 50% and 55% as abnormal and serum albumin was less sensitive. Using total SBA, combining the fasting level and AUC identified 100% as abnormal; using CG, 85% of these patients were detected. As a stepwise cost-effective approach, the fasting level of SBAs can identify most patients with anicteric liver disease. In cases with normal fasting levels where liver disease is suspected, the three-point AUC determination may identify additional patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3731971     DOI: 10.1007/bf01296044

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Serum-bile-acid levels in liver disease.

Authors:  E C OSBORN; I D WOOTTON; L da SILVA; S SHERLOCK
Journal:  Lancet       Date:  1959-12-12       Impact factor: 79.321

2.  Radioimmunoassay of serum bile acid levels in biopsy-proved cirrhosis.

Authors:  C A Dasher; B I Hirschowitz; J G Spenney; R G Gibson; A A Mihas
Journal:  South Med J       Date:  1977-08       Impact factor: 0.954

Review 3.  The enterohepatic circulation of bile acids in man.

Authors:  A F Hofmann
Journal:  Clin Gastroenterol       Date:  1977-01

4.  Assessment of activity in chronic active liver disease. Serum bile acids compared with conventional tests and histology.

Authors:  M G Korman; A F Hofmann; W H Summerskill
Journal:  N Engl J Med       Date:  1974-06-20       Impact factor: 91.245

5.  Postprandial serum bile acid for the detection of hepatobiliary disease.

Authors:  N Kaplowitz; E Kok; N B Javitt
Journal:  JAMA       Date:  1973-07-16       Impact factor: 56.272

6.  Response of total and individual serum bile acids to endogenous and exogenous bile acid input to the enterohepatic circulation.

Authors:  S G De Barros; W F Balistreri; R D Soloway; S G Weiss; P C Miller; K Soper
Journal:  Gastroenterology       Date:  1982-04       Impact factor: 22.682

7.  Serum bile acids as related to bile acid secretion in liver disease.

Authors:  E A Shaffer; E R Gordon
Journal:  Am J Dig Dis       Date:  1978-05

8.  Specific 125I-radioimmunoassay for cholyglycine, a bile acid, in serum.

Authors:  P Miller; S Weiss; M Cornell; J Dockery
Journal:  Clin Chem       Date:  1981-10       Impact factor: 8.327

9.  Dynamics of the enterohepatic circulation of bile acids. Postprandial serum concentrations of conjugates of cholic acid in health, cholecystectomized patients, and patients with bile acid malabsorption.

Authors:  N F LaRusso; M G Korman; N E Hoffman; A F Hofmann
Journal:  N Engl J Med       Date:  1974-10-03       Impact factor: 91.245

10.  Serum bile acids in liver disease.

Authors:  G Neale; B Lewis; V Weaver; D Panveliwalla
Journal:  Gut       Date:  1971-02       Impact factor: 23.059

View more
  1 in total

1.  Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity.

Authors:  N N Ahmad; A Pfalzer; L M Kaplan
Journal:  Int J Obes (Lond)       Date:  2013-04-09       Impact factor: 5.095

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.